Peter L. M. Jansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Peter L. M. Jansen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Michael Müller
Faculty of Medicine and Health Sciences, Norwich Medical School, University of East Anglia, Norwich, UK
4 shared publications Ekkehard Sturm
Department of Hepatology and Gastroenterology and Department of Pediatrics, University Hospital Groningen, 9713 GZ Groningen, Netherlands
3 shared publications- Folkert Kuipers
European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications A. de Jager-Krikken
1 shared publicationA.T.M.G. Tiebosch
1 shared publicationAlie de Jager-Krikken
1 shared publication
Latest Publications
- Open Access
- 1 December 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (51) , 35630-35637
Up-regulation and Cytoprotective Role of Epithelial Multidrug Resistance-associated Protein 1 in Inflammatory Bowel Disease
- 1 December 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (51) , 35630-35637
Open AccessUp-regulation and Cytoprotective Role of Epithelial Multidrug Resistance-associated Protein 1 in Inflammatory Bowel Disease
- 1 October 2003
- Published by Elsevier in The Lancet
- Vol. 362 (9390) , 1090-1091
Paediatric cholestasis: is villin the villain?
- 1 October 2003
- Published by Elsevier in The Lancet
- Vol. 362 (9390) , 1090-1091
Paediatric cholestasis: is villin the villain?
- Open Access
- 22 September 2003
- Published by Wiley in Liver International
- Vol. 23 (5) , 315-322
Genetic cholestasis, causes and consequences for hepatobiliary transport
Bile salts take part in an efficient enterohepatic circulation in which most of the secreted bile salts are reclaimed by absorption in the terminal ileum. In the liver, the sodium‐dependent taurocholate transporter at the basolateral (sinusoidal) membrane and the bile salt export pump at the canalicular membrane mediate hepatic uptake and hepatobiliary secretion of bile salts. Canalicular secretion is the driving force for the enterohepatic cycling of bile salts and most genetic diseases are caused by defects of canalicular secretion. Impairment of bile flow leads to adaptive changes in the expression of transporter proteins and enzymes of the cytochrome P‐450 system involved in the metabolism of cholesterol and bile acids. Bile salts act as ligands for transcription factors. As such, they stimulate or inhibit the transcription of genes encoding transporters and enzymes involved in their own metabolism. Together these changes appear to serve mainly a hepatoprotective function. Progressive familial intrahepatic cholestasis (PFIC) results from mutations in various genes encoding hepatobiliary transport proteins. Mutations in theFIC1gene cause relapsing or permanent cholestasis. The relapsing type of cholestasis is called benign recurrent intrahepatic cholestasis, the permanent type of cholestasis PFIC type 1. PFIC type 2 results from mutations in the bile salt export pump (BSEP) gene. This is associated with permanent cholestasis since birth. Serum gamma‐glutamyltransferase (gamma‐GT) activity is low to normal in PFIC types 1 and 2. Bile diversion procedures, causing a decreased bile salt pool, have a beneficial effect in a number of patients with these diseases. However, liver transplantation is often necessary. PFIC type 3 is caused by mutations in theMDR3gene. MDR3 is a phospholipid translocator in the canalicular membrane. Because of the inability to secrete phospholipids, patients with PFIC type 3 produce bile acid‐rich toxic bile that damages the intrahepatic bile ducts. Serum gamma‐GT activity is elevated in these patients. Ursodeoxycholic acid therapy is useful for patients with a partial defect. Liver transplantation is a more definitive therapy for these patients.
- 22 September 2003
- Published by Wiley in Liver International
- Vol. 23 (5) , 315-322
Open AccessGenetic cholestasis, causes and consequences for hepatobiliary transport
Bile salts take part in an efficient enterohepatic circulation in which most of the secreted bile salts are reclaimed by absorption in the terminal ileum. In the liver, the sodium‐dependent taurocholate transporter at the basolateral (sinusoidal) membrane and the bile salt export pump at the canalicular membrane mediate hepatic uptake and hepatobiliary secretion of bile salts. Canalicular secretion is the driving force for the enterohepatic cycling of bile salts and most genetic diseases are caused by defects of canalicular secretion. Impairment of bile flow leads to adaptive changes in the expression of transporter proteins and enzymes of the cytochrome P‐450 system involved in the metabolism of cholesterol and bile acids. Bile salts act as ligands for transcription factors. As such, they stimulate or inhibit the transcription of genes encoding transporters and enzymes involved in their own metabolism. Together these changes appear to serve mainly a hepatoprotective function. Progressive familial intrahepatic cholestasis (PFIC) results from mutations in various genes encoding hepatobiliary transport proteins. Mutations in theFIC1gene cause relapsing or permanent cholestasis. The relapsing type of cholestasis is called benign recurrent intrahepatic cholestasis, the permanent type of cholestasis PFIC type 1. PFIC type 2 results from mutations in the bile salt export pump (BSEP) gene. This is associated with permanent cholestasis since birth. Serum gamma‐glutamyltransferase (gamma‐GT) activity is low to normal in PFIC types 1 and 2. Bile diversion procedures, causing a decreased bile salt pool, have a beneficial effect in a number of patients with these diseases. However, liver transplantation is often necessary. PFIC type 3 is caused by mutations in theMDR3gene. MDR3 is a phospholipid translocator in the canalicular membrane. Because of the inability to secrete phospholipids, patients with PFIC type 3 produce bile acid‐rich toxic bile that damages the intrahepatic bile ducts. Serum gamma‐GT activity is elevated in these patients. Ursodeoxycholic acid therapy is useful for patients with a partial defect. Liver transplantation is a more definitive therapy for these patients.
- Open Access
ATP binding cassette transporter gene expression in rat liver progenitor cells
Background and aim: Liver regeneration after severe liver damage depends in part on proliferation and differentiation of hepatic progenitor cells (HPCs). Under these conditions they must be able to withstand the toxic milieu of the damaged liver. ATP binding cassette (ABC) transporters are cytoprotective efflux pumps that may contribute to the preservation of these cells. The aim of this study was to determine the ABC transporter phenotype of HPCs. Methods: HPC activation was studied in rats treated with 2- acetylaminofluorene (2-AAF) followed by partial hepatectomy (PHx). ABC transporter gene expression was determined by real time detection reverse transcription-polymerase chain reaction in isolated HPCs, hepatocytes, cholangiocytes, and cultured progenitor cell-like RLF ϕ 13 cells and by immunohistochemistry of total liver samples. ABC transporter efflux activity was studied in RLF ϕ 13 cells by flow cytometry. Results: 2-AAF/PHx treated animals showed increased hepatic mRNA levels of the genes encoding multidrug resistance proteins Mdr1b , Mrp1 , and Mrp3 . Immunohistochemistry demonstrated expression of Mrp1 and Mrp3 proteins in periportal progenitor cells and of the Mdr1b protein in periportal hepatocytes. Freshly isolated Thy-1 positive cells and cultured RLF ϕ 13 progenitor cells highly expressed Mrp1 and Mrp3 mRNA while the hepatocyte specific transporters Mdr2 , Bsep , Mrp2 , and Mrp6 were only minimally expressed. Blocking Mrp activity by MK-571 resulted in accumulation of the Mrp specific substrate carboxyfluorescein in RLF ϕ 13 cells. Conclusion: HPCs express high levels of active Mrp1 and Mrp3. These may have a cytoprotective role in conditions of severe hepatotoxicity.
Open AccessATP binding cassette transporter gene expression in rat liver progenitor cells
Background and aim: Liver regeneration after severe liver damage depends in part on proliferation and differentiation of hepatic progenitor cells (HPCs). Under these conditions they must be able to withstand the toxic milieu of the damaged liver. ATP binding cassette (ABC) transporters are cytoprotective efflux pumps that may contribute to the preservation of these cells. The aim of this study was to determine the ABC transporter phenotype of HPCs. Methods: HPC activation was studied in rats treated with 2- acetylaminofluorene (2-AAF) followed by partial hepatectomy (PHx). ABC transporter gene expression was determined by real time detection reverse transcription-polymerase chain reaction in isolated HPCs, hepatocytes, cholangiocytes, and cultured progenitor cell-like RLF ϕ 13 cells and by immunohistochemistry of total liver samples. ABC transporter efflux activity was studied in RLF ϕ 13 cells by flow cytometry. Results: 2-AAF/PHx treated animals showed increased hepatic mRNA levels of the genes encoding multidrug resistance proteins Mdr1b , Mrp1 , and Mrp3 . Immunohistochemistry demonstrated expression of Mrp1 and Mrp3 proteins in periportal progenitor cells and of the Mdr1b protein in periportal hepatocytes. Freshly isolated Thy-1 positive cells and cultured RLF ϕ 13 progenitor cells highly expressed Mrp1 and Mrp3 mRNA while the hepatocyte specific transporters Mdr2 , Bsep , Mrp2 , and Mrp6 were only minimally expressed. Blocking Mrp activity by MK-571 resulted in accumulation of the Mrp specific substrate carboxyfluorescein in RLF ϕ 13 cells. Conclusion: HPCs express high levels of active Mrp1 and Mrp3. These may have a cytoprotective role in conditions of severe hepatotoxicity.
- 20 June 2003
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 128 (S 2) , 107-109
Genetic cholestasis
PFIC = Progressive familial intrahepatic cholestasis BRIC = benign recurrent intrahepatic cholestasis BSEP = bile salt export pump OATP = organic anion transporting polypeptide MRP = multidrug resistance related protein. Bile salts are the predominant organic solutes in bile, and their vectorial secretion from liver to bile represents the major driving force for hepatic bile formation. Disturbances of bile salt transport across the basolateral and apical domains of the hepatocyte plasma membrane are important causes of acquired and genetic forms of cholestatic liver disease in humans. Defective bile salt secretion not only leads to progressive liver damage, but also metabolic derangements and malnutrition secondary to reduced intestinal absorption of lipids and fat-soluble vitamins.
- 20 June 2003
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 128 (S 2) , 107-109
Genetic cholestasis
PFIC = Progressive familial intrahepatic cholestasis BRIC = benign recurrent intrahepatic cholestasis BSEP = bile salt export pump OATP = organic anion transporting polypeptide MRP = multidrug resistance related protein. Bile salts are the predominant organic solutes in bile, and their vectorial secretion from liver to bile represents the major driving force for hepatic bile formation. Disturbances of bile salt transport across the basolateral and apical domains of the hepatocyte plasma membrane are important causes of acquired and genetic forms of cholestatic liver disease in humans. Defective bile salt secretion not only leads to progressive liver damage, but also metabolic derangements and malnutrition secondary to reduced intestinal absorption of lipids and fat-soluble vitamins.
- 1 December 2001
- Published by Elsevier in Journal of Hepatology
- Vol. 35 (6) , 811-813
Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease
- 1 December 2001
- Published by Elsevier in Journal of Hepatology
- Vol. 35 (6) , 811-813
Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease
- 1 December 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 34 (6) , 1067-1074
Genes and cholestasis
- 1 December 2001
- Published by Wolters Kluwer Health in Hepatology
- Vol. 34 (6) , 1067-1074
Genes and cholestasis
- 9 December 2000
- Vol. 144 (50) , 2384-91
[Bile formation and cholestasis].
Transport proteins in hepatocytes and bile duct epithelium mediate uptake and secretion of cholephilic compounds in the liver and are involved in bile formation. Many of these proteins have recently been cloned and characterized and appear to belong to large gene families. Apart from the liver these proteins are expressed in the blood-brain barrier, placenta, kidneys, lungs, intestine and seminiferous tubules. Prokaryotes and yeasts contain similar proteins. In cancer cells they are involved in multidrug resistance. Some genetic cholestatic liver diseases, including progressive familial intrahepatic cholestasis, Dubin-Johnson syndrome, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy result from mutations in transport protein genes. These proteins also play a role in drug-induced liver disease and in primary biliary cirrhosis. Cyclosporine and oestradiol (glucuronide) for instance inhibit bile salt export protein (BSEP).
- 9 December 2000
- Vol. 144 (50) , 2384-91
[Bile formation and cholestasis].
Transport proteins in hepatocytes and bile duct epithelium mediate uptake and secretion of cholephilic compounds in the liver and are involved in bile formation. Many of these proteins have recently been cloned and characterized and appear to belong to large gene families. Apart from the liver these proteins are expressed in the blood-brain barrier, placenta, kidneys, lungs, intestine and seminiferous tubules. Prokaryotes and yeasts contain similar proteins. In cancer cells they are involved in multidrug resistance. Some genetic cholestatic liver diseases, including progressive familial intrahepatic cholestasis, Dubin-Johnson syndrome, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy result from mutations in transport protein genes. These proteins also play a role in drug-induced liver disease and in primary biliary cirrhosis. Cyclosporine and oestradiol (glucuronide) for instance inhibit bile salt export protein (BSEP).
- Open Access
- 1 January 2000
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 14 (3) , 233-238
Genetic Cholestasis: Lessons from the Molecular Physiology of Bile Formation
Progressive familial intrahepatic cholestasis (PFIC) is a group of severe genetic cholestatic liver diseases of early life. PFIC types 1 and 2 are characterized by cholestasis and a low to normal serum gamma-glutamyltransferase (GGT) activity, whereas in PFIC type 3, the serum GGT activity is elevated. PFIC types 1 and 2 occur due to mutations in loci at chromosome 18 and chromosome 2, respectively. The pathophysiology of PFIC type 1 is not well understood. PFIC types 2 and 3 are caused by transport defects in the liver affecting the hepatobiliary secretion of bile acids and phospholipids, respectively. Benign recurrent intrahepatic cholestasis (BRIC) is linked to a mutation in the same familial intrahepatic cholestasis 1 locus at chromosome 18. Defects of bile acid synthesis may be difficult to differentiate from these transport defects.Intrahepatic cholestasis of pregnancy (ICP) appears to be related to these cholestatic diseases. For example, heterozygosity in families with PFIC type 3 is associated with ICP, but ICP has also been reported in families with BRIC.In Dubin-Johnson syndrome there is no cholestasis; only the hepatobiliary transport of conjugated bilirubin is affected. This, therefore, is a mild disease, and patients have a normal lifespan.
- 1 January 2000
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 14 (3) , 233-238
Open AccessGenetic Cholestasis: Lessons from the Molecular Physiology of Bile Formation
Progressive familial intrahepatic cholestasis (PFIC) is a group of severe genetic cholestatic liver diseases of early life. PFIC types 1 and 2 are characterized by cholestasis and a low to normal serum gamma-glutamyltransferase (GGT) activity, whereas in PFIC type 3, the serum GGT activity is elevated. PFIC types 1 and 2 occur due to mutations in loci at chromosome 18 and chromosome 2, respectively. The pathophysiology of PFIC type 1 is not well understood. PFIC types 2 and 3 are caused by transport defects in the liver affecting the hepatobiliary secretion of bile acids and phospholipids, respectively. Benign recurrent intrahepatic cholestasis (BRIC) is linked to a mutation in the same familial intrahepatic cholestasis 1 locus at chromosome 18. Defects of bile acid synthesis may be difficult to differentiate from these transport defects.Intrahepatic cholestasis of pregnancy (ICP) appears to be related to these cholestatic diseases. For example, heterozygosity in families with PFIC type 3 is associated with ICP, but ICP has also been reported in families with BRIC.In Dubin-Johnson syndrome there is no cholestasis; only the hepatobiliary transport of conjugated bilirubin is affected. This, therefore, is a mild disease, and patients have a normal lifespan.
- 1 December 1999
- Published by Elsevier in Gastroenterology
- Vol. 117 (6) , 1370-1379
Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis
- 1 December 1999
- Published by Elsevier in Gastroenterology
- Vol. 117 (6) , 1370-1379
Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis